Vaishali Pharma (VAISHALI) Q3 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 were approved and reviewed without qualification by auditors.

• Board approved a preferential allotment of up to 6,123,000 equity shares at ₹20 per share, aggregating to ₹12.25 crore, subject to shareholder and regulatory approvals.

Financial highlights

• Standalone revenue for Q3 FY26 was ₹2,465.19 lakh, down from ₹3,344.63 lakh in Q2 FY26 and ₹2,791.43 lakh in Q3 FY25.

• Standalone net profit for Q3 FY26 was ₹130.14 lakh, up from ₹118.46 lakh in Q2 FY26 but down from ₹144.26 lakh in Q3 FY25.

• Nine-month standalone revenue was ₹8,184.53 lakh, up from ₹6,677.98 lakh year-over-year.

• Nine-month standalone net profit was ₹376.52 lakh, down from ₹510.99 lakh year-over-year.

• Consolidated Q3 FY26 net profit was ₹131.79 lakh, including ₹1.65 lakh share of profit from associate.

Outlook and guidance

• Preferential issue aims to raise capital for future growth and expansion, subject to approvals.